Literature DB >> 12397426

Pigmentary retinopathy in patients with the MELAS mutation 3243A-->G in mitochondrial DNA.

Terho Latvala1, Eila Mustonen, Raimo Uusitalo, Kari Majamaa.   

Abstract

BACKGROUND: Our objective was to determine the penetrance of retinal pigment epithelium (RPE) abnormalities and other ophthalmologic manifestations in patients with the 3243A-->G mutation in mitochondrial DNA.
METHODS: Adult members in two generations were examined from a population-based cohort of 13 pedigrees with 3243A-->G. Twenty-six patients underwent a thorough ophthalmological examination. A chart review was carried out on an additional 44 patients.
RESULTS: Paramacular RPE atrophy and areas of hyperpigmentation were found in 10 patients (38%; 95% confidence interval 20-59%). Electroretinography was normal in only one of the eight patients tested, whereas dark adaptation was abnormal in two. RPE abnormalities were associated with more severe clinical phenotypes and higher degrees of 3243A-->G mutation heteroplasmy in muscle. Ten patients had diabetes mellitus, nine of whom had also RPE abnormalities. This finding, however, reflected the severity of the phenotype, and diabetic retinopathy was confidently diagnosed in only two patients. External ophthalmoplegia was detected in occasional patients.
CONCLUSION: RPE abnormalities were found in this population-based cohort at a frequency that was lower than that reported earlier. RPE abnormalities were associated with more severe phenotypes, suggesting that they are expressed in patients with syndromic features. RPE abnormalities and diabetes mellitus co-occurred frequently, but diabetic retinopathy was not common.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397426     DOI: 10.1007/s00417-002-0555-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

Review 1.  The neuro-ophthalmology of mitochondrial disease.

Authors:  J Alexander Fraser; Valérie Biousse; Nancy J Newman
Journal:  Surv Ophthalmol       Date:  2010-05-14       Impact factor: 6.048

Review 2.  Macular pattern dystrophy and homonymous hemianopia in MELAS syndrome.

Authors:  Radua Kamal-Salah; Isabel Baquero-Aranda; María Del Mar Grana-Pérez; Jose Manuel García-Campos
Journal:  BMJ Case Rep       Date:  2015-03-12

3.  Macular findings expedite accurate diagnosis of MIDD in a young female patient with newly diagnosed diabetes.

Authors:  John M Bryan; Cole N Rojas; Rukhsana G Mirza
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-07

4.  Retinal dystrophy associated with a single-base deletion mutation in mitochondrial DNA 3271 in patient with MELAS syndrome.

Authors:  Kenji Ozawa; Kiyofumi Mochizuki; Yusuke Manabe; Nobuaki Yoshikura; Takayoshi Shimohata; Ichizo Nishino; Yu-Ichi Goto
Journal:  Doc Ophthalmol       Date:  2019-01-30       Impact factor: 2.379

5.  Mitochondrial proteomics of the retinal pigment epithelium at progressive stages of age-related macular degeneration.

Authors:  Curtis L Nordgaard; Pabalu P Karunadharma; Xiao Feng; Timothy W Olsen; Deborah A Ferrington
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-14       Impact factor: 4.799

6.  Mitochondrial DNA abnormalities in ophthalmological disease.

Authors:  Grainne S Gorman; Robert W Taylor
Journal:  Saudi J Ophthalmol       Date:  2011-02-18

Review 7.  Macular dystrophy associated with the mitochondrial DNA A3243G mutation: pericentral pigment deposits or atrophy? Report of two cases and review of the literature.

Authors:  Alejandra Daruich; Alexandre Matet; François-Xavier Borruat
Journal:  BMC Ophthalmol       Date:  2014-06-06       Impact factor: 2.209

8.  Retinal biomarkers of Cerebral Small Vessel Disease: A systematic review.

Authors:  Elena Biffi; Zachary Turple; Jessica Chung; Alessandro Biffi
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.240

Review 9.  Endocrine disorders in mitochondrial disease.

Authors:  Andrew M Schaefer; Mark Walker; Douglass M Turnbull; Robert W Taylor
Journal:  Mol Cell Endocrinol       Date:  2013-06-13       Impact factor: 4.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.